{"url":"https://lda.senate.gov/api/v1/filings/130a7604-c528-4781-a842-0ec1d47e1422/?format=json","filing_uuid":"130a7604-c528-4781-a842-0ec1d47e1422","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2021,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/130a7604-c528-4781-a842-0ec1d47e1422/print/","filing_document_content_type":"text/html","income":null,"expenses":"110000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Anna Jones","dt_posted":"2021-07-20T11:38:10.457000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"5980 Horton Street","registrant_address_2":"Suite 105","registrant_different_address":false,"registrant_city":"Emeryville","registrant_state":"CA","registrant_zip":"94608","registrant":{"id":401106060,"url":"https://lda.senate.gov/api/v1/registrants/401106060/?format=json","house_registrant_id":null,"name":"ZYMERGEN INC.","description":"Biofacturing company","address_1":"5980 Horton Street","address_2":"Suite 105","address_3":null,"address_4":null,"city":"Emeryville","state":"CA","state_display":"California","zip":"94608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MINA KIM","contact_telephone":"+1 415-706-0229","dt_updated":"2022-04-06T16:07:19.567075-04:00"},"client":{"id":210500,"url":"https://lda.senate.gov/api/v1/clients/210500/?format=json","client_id":12,"name":"ZYMERGEN INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-03-23"},"lobbying_activities":[{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Issues related to domestic biomanufacturing investment; pharmaceutical supply chain resilience; nominations; biomedicine, biotech, and the bioeconomy","foreign_entity_issues":"Foreign entities identified on form LD-1 have an interest in the lobbying issues.","lobbyists":[{"lobbyist":{"id":101171,"prefix":null,"prefix_display":null,"first_name":"ANNA","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}